Navigation Links
ChromaDex Announces 2008 Year End Financial Results
Date:4/3/2009

IRVINE, Calif., April 3 /PRNewswire-FirstCall/ -- ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the 2008 Fiscal Year. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.07 per share for the twelve months ended January 3, 2009.

As of January 3, 2009, cash, cash equivalents, and marketable securities totaled $1 million.

"The FDA started implementing Good Manufacturing Practices for dietary supplements in June 2008," said Frank Jaksch, CEO and co-founder of ChromaDex. "There is a rapidly growing awareness both at the consumer and government regulatory level of the need for reference standards, analytical methods and other quality assurance methods to insure that products on the shelf not only contain what is claimed on the label, but are also safe and effective. We are confident that the increased awareness and demand for products that are healthy, natural, organic or green, will continue to provide an opportunity for ChromaDex. Additionally, we will continue to invest in products, services and intellectual property that will enable us to remain the reference standards market leader for the dietary supplement, food, beverage, personal care, and sport nutrition markets."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during 2008 of $4,506,301 as compared to $4,754,073 for the same period in 2007. The net loss attributable to common stockholders for the twelve months ended January 3, 2009, was $2,104,476 as compared to a net loss of $189,875 for the same period in 2007. The company notes that as a result of its closing of the reverse merger acquisition of Cody Resources, Inc. on June 20, 2008, investors are cautioned that the company's historical performance is not directly comparable.

About ChromaDex

ChromaDex is a leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Corporation

10005 Muirlands Blvd, Suite G

Irvine, CA 92618

Phone 949-419-0288

Fax 949-419-0294

Email info@chromadex.com

www.chromadex.com

    ChromaDex Corporation and Subsidiaries

    Consolidated Statements of Operations
    Years Ended January 3, 2009 and December 29, 2007

                                                    2008        2007

    Sales                                        $4,506,301  $4,754,073

    Cost of goods sold                            3,274,800   3,122,461

     Gross profit                                 1,231,501   1,631,612

    Operating expenses:
     Selling                                        720,519     387,816
     General and administrative                   2,579,015   1,421,516
                                                  3,299,534   1,809,332

     Operating loss                              (2,068,033)   (177,720)

    Nonoperating (income) expenses:
     Interest expense                                70,079      31,815
     Interest and other income                      (33,636)    (19,660)
                                                     36,443      12,155

     Net loss                                   $(2,104,476)  $(189,875)


    Basic and Diluted loss per common share          $(0.07)     $(0.01)


    Basic and Diluted average common shares
     outstanding                                 28,312,934  26,514,481



'/>"/>
SOURCE ChromaDex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
3. China Agri-Business Announces 2008 Operating Results
4. Verenium Announces Organizational Changes
5. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
6. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
7. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
8. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
9. China Biologic Products Announces Strong 2008 Results
10. Senetek PLC Announces New Investor Communication Hotline
11. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):